Dry Eye

The nutritional supplement comprised of a proprietary blend of lutein, zeaxanthin isomers, curcumin, and vitamin D3 improved tear production, tear film break-up time, and tear osmolarity, among others.

UC Berkeley’s Herbert Wertheim School of Optometry and Vision Science integrated the new laser in the beginning of March in its dry eye clinic for treatment of meibomian gland dysfunction.

Evaluating and managing lid margin disease and meibomian gland dysfunction.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population," which could be due to incomplete eyelid closure, eye discomfort, and mental stress.

Warm compresses are an invaluable step in the treatment of dry eye.

The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.

Multiple symptomatic improvements, as well as tear film break-up time improvements and a reduction in ocular pain, were noted.

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis.

Education, together with strong recommendations, in-office retail, habit hacks, and follow-up visits, supports patient compliance.

Phase 3 of the randomized, double-masked, placebo-controlled study had a primary end point to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome.

By targeting tear evaporation, F6H8 ushers in a new era of dry eye treatment.

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

AR-15512 is a topical transient receptor potential melastatin 8 (TRPM8) agonist designed to treat the signs and symptoms of DED via increased tear production.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

Dry eye disease incidence rates vary markedly depending on the eye care practice.

Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

A look back at some of the biggest stories in ophthalmology in 2023.

Amy Nau, OD, discusses a challenging case of Demodex infestation in a 32-year-old male suffering from severe anxiety due to Rosacea and Demodex.

Amy Nau, DO, presents another case of Demodex in a female patient, highlighting the multifaceted approach required for successful treatment.

Dr Amy Nau shares a patient case involving a female with Demodex infestation, ultimately treated with lotilaner.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

By taking a proactive approach to treatment, identify the “silent sufferers.”

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.

These toxic offenders can be found in various pathways and can pollute the ocular surface.

Educating patients about the importance of consistent care is key.